In any case Anavex will have to file data from the trials. For that to happen the trials first have to readout. All this is true also for provisional or accelerated approval.
As for a surrogate endpoint biomarker, I can’t quite see we have one.
The primary and secondary endpoints as defined in the trial protocols has a good chance of being met.
Market Data 
Markets 
AI
